ArticleMetabolites2025
Differential Expression of Lipid Metabolism Genes, CROT and ABCG1, in Obese Patients with Comorbid Depressive Disorder and Risk of MASLD.
Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cumulative lipid exposure in young adulthood and risk of midlife MASLD.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThere is accumulating evidence supporting a bidirectional relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and depressive disorder (DD), with possible genetic factors related to hepatic lipid metabolism. Our aim was to analyse the prevalence of DD in patients with obesity at risk of MASLD, and to evaluate the hepatic expression of genes involved in lipid metabolism, in patients with DD.
methodsIn 152 patients with morbid obesity who underwent bariatric surgery, medical data, blood and liver samples were collected. Liver biopsies were scored for MASLD staging were used for gene expression analysis.
resultsThe DD prevalence in this cohort was 29.6%, and patients with DD had a significantly higher hepatic expression of the
conclusionsIn this study, individuals with morbid obesity demonstrated an elevated prevalence of DD. Moreover, hepatic genetic dysregulation of lipid metabolism may influence the interplay between MASLD and DD in patients with morbid obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.